A detailed history of Lynch & Associates transactions in Amgen Inc stock. As of the latest transaction made, Lynch & Associates holds 5,325 shares of AMGN stock, worth $1.4 Million. This represents 0.37% of its overall portfolio holdings.

Number of Shares
5,325
Previous 4,980 6.93%
Holding current value
$1.4 Million
Previous $1.56 Million 10.22%
% of portfolio
0.37%
Previous 0.35%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

BUY
$309.38 - $337.38 $106,736 - $116,396
345 Added 6.93%
5,325 $1.72 Million
Q2 2024

Aug 06, 2024

BUY
$262.75 - $319.31 $101,421 - $123,253
386 Added 8.4%
4,980 $1.56 Million
Q1 2024

Apr 09, 2024

BUY
$268.87 - $324.56 $283,657 - $342,410
1,055 Added 29.81%
4,594 $1.31 Million
Q4 2023

Jan 08, 2024

BUY
$255.7 - $288.46 $660,217 - $744,803
2,582 Added 269.8%
3,539 $1.02 Million
Q3 2023

Oct 24, 2023

BUY
$218.65 - $271.46 $209,248 - $259,787
957 New
957 $257,000

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $141B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Lynch & Associates Portfolio

Follow Lynch & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lynch & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Lynch & Associates with notifications on news.